科倫藥業(002422.SZ):中長鏈脂肪乳/氨基酸(16)/葡萄糖(16%)注射液國內首家通過一致性評價
格隆匯4月29日丨科倫藥業(002422.SZ)宣佈,近日公司的中長鏈脂肪乳/氨基酸(16)/葡萄糖(16%)注射液(“全合一”腸外營養三腔袋)國內首家通過一致性評價並獲得藥品補充申請批准通知書,主要用於功能不全或不能經口/腸道攝取營養的輕至中度分解代謝患者的營養補充。
腸外營養在危重、嚴重創傷等患者的救治中具有重要作用,可快速提供機體所需營養物質、促進患者康復、改善疾病預後。目前公司已獲批上市11個腸外營養新產品,覆蓋單袋、雙室袋、三腔袋包裝形式,差異化的產品配方可滿足不同類型(肝功能受損、圍手術期、危重症等)和不同能量需求患者的營養治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.